We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

121 hedge funds and large institutions have $227M invested in Enanta Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 43 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $870K

127% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 11

63% more capital invested

Capital invested by funds: $139M → $227M (+$87.7M)

13% more funds holding

Funds holding: 107 → 121 (+14)

2.57% more ownership

Funds ownership: 86.28% → 88.84% (+2.6%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

26% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 43

Holders
121
Holders Change
+14
Holders Change %
+13.08%
% of All Funds
1.59%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
32
Reduced
43
Closed
11
Calls
$3.7M
Puts
$870K
Net Calls
+$2.83M
Net Calls Change
+$2.43M

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$11.4M
2
CC
Commodore Capital
New York
+$6.39M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.4M
4
N
Nuveen
North Carolina
+$958K
5
SC
Stempoint Capital
New York
+$601K

Top Sellers

1
Marshall Wace
Marshall Wace
United Kingdom
-$4.65M
2
Millennium Management
Millennium Management
New York
-$4.08M
3
SCM
Stonepine Capital Management
Oregon
-$2.39M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$1.35M
5
SCM
Sio Capital Management
New York
-$1.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$1.5M -$67.9K -8,500 -6%
JP Morgan Chase
27
JP Morgan Chase
New York
$1.48M -$52.9K -6,616 -5%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$1.4M +$348K +43,545 +59%
PP
29
PDT Partners
New York
$1.03M -$5.83K -730 -0.8%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$928K +$501K +62,710 +424%
SC
31
Stempoint Capital
New York
$900K +$601K +75,194 New
SEI Investments
32
SEI Investments
Pennsylvania
$884K – – –
Two Sigma Investments
33
Two Sigma Investments
New York
$727K -$142K -17,733 -23%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$724K +$40.1K +5,019 +9%
Invesco
35
Invesco
Georgia
$715K -$25.5K -3,186 -5%
Assenagon Asset Management
36
Assenagon Asset Management
Luxembourg
$649K -$417K -52,123 -49%
SFI
37
Susquehanna Fundamental Investments
Pennsylvania
$604K – – –
CSS
38
Cubist Systematic Strategies
Connecticut
$598K +$399K +49,983 New
American Century Companies
39
American Century Companies
Missouri
$581K +$62.3K +7,791 +19%
Barclays
40
Barclays
United Kingdom
$498K -$50.1K -6,267 -13%
Man Group
41
Man Group
United Kingdom
$481K +$321K +40,156 New
IC
42
IEQ Capital
California
$451K -$21.3K -2,662 -7%
GCM
43
Graham Capital Management
Connecticut
$447K +$149K +18,593 +99%
QCM
44
Quantinno Capital Management
New York
$444K +$198K +24,785 +201%
PA
45
PharVision Advisers
Florida
$429K +$286K +35,846 New
Thrivent Financial for Lutherans
46
Thrivent Financial for Lutherans
Minnesota
$407K -$414K -51,793 -60%
Bank of Montreal
47
Bank of Montreal
Ontario, Canada
$405K – – –
AllianceBernstein
48
AllianceBernstein
Tennessee
$404K – – –
HF
49
HRT Financial
New York
$397K +$265K +33,188 New
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$370K -$11.2K -1,399 -4%
1
2
3 4 5

ENTA Hedge Fund Activity: Q3 2025 in Review

121 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2025, worth a combined $227M — up 63% from $139M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ENTA positions and 11 closed out — a net gain of 14 holders — while 32 added to existing stakes and 43 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $11.4M. The largest seller was Marshall Wace, cutting an estimated $4.65M.

  • 121 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2025, up from 107 in Q2 2025.
  • Funds reported $227M of Enanta Pharmaceuticals stock for Q3 2025, up 63% quarter-over-quarter.
  • 25 funds opened new Enanta Pharmaceuticals positions in Q3 2025 and 11 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2025 was Janus Henderson Group, an estimated $11.4M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2025 was Marshall Wace, an estimated $4.65M sold.

Based on aggregated 13F filings for Q3 2025.